Literature DB >> 3619211

Vascular components of ARDS. Clinical pulmonary hemodynamics and morphology.

W M Zapol, R Jones.   

Abstract

Mild pulmonary artery hypertension (PAP, 29.6 +/- 10.6 mm Hg, mean +/- SD) due to a 3-fold elevation of pulmonary vascular resistance (PVR, 2.2 +/- 1.1 mm Hg X L/min) is a common finding in severe ARDS. A vasodilator such as nitroprusside (151 micrograms/kg X min) can be administered in early ARDS and will lower PAP and PAOP (capillary wedge pressure) while increasing cardiac output (CO) from 6.9 to 8.75 L/min X M2 and venous admixture from 23% to 31.6%. This suggests diffuse vasoconstriction is present in early ARDS. In 19 patients with severe ARDS, 13 had vascular occlusions on balloon occlusion angiography, and these occlusions correlated with increased post mortem counts of PA thrombi. At autopsy, there was a considerable increase of PA medial thickness and a reduction of lumen diameter. This hemodynamic and morphologic evidence suggests both vasoconstrictor and anatomic changes play major roles elevating the PVR in ARDS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619211     DOI: 10.1164/ajrccm/136.2.471

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

Review 1.  The adult respiratory distress syndrome.

Authors:  N F Voelkel
Journal:  Klin Wochenschr       Date:  1989-06-01

2.  Intestinal ischemia and reperfusion impairs vasomotor functions of pulmonary vascular bed.

Authors:  C Köksoy; M A Kuzu; H Ergün; E Demirpençe; B Zülfikaroglu
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.

Authors:  Jean-Christophe Richard; Fabienne Bregeon; Véronique Leray; Didier Le Bars; Nicolas Costes; Christian Tourvieille; Franck Lavenne; Mojgan Devouassoux-Shisheboran; Gerard Gimenez; Claude Guerin
Journal:  Intensive Care Med       Date:  2007-08-02       Impact factor: 17.440

4.  The monitoring of acute cor pulmonale is still necessary in "Berlin" ARDS patients.

Authors:  D Chiumello; A Pesenti
Journal:  Intensive Care Med       Date:  2013-08-14       Impact factor: 17.440

5.  Rapidly reversible acute cor pulmonale after intravenous injection of crushed dextromoramide (Palfium) pills.

Authors:  T Jullien; B Valtier; A Vieillard-Baron; J P Bourdarias; F Jardin
Journal:  Intensive Care Med       Date:  1996-03       Impact factor: 17.440

Review 6.  Physiology-guided management of hemodynamics in acute respiratory distress syndrome.

Authors:  Gustavo A Cortes-Puentes; Richard A Oeckler; John J Marini
Journal:  Ann Transl Med       Date:  2018-09

7.  Randomized clinical trial of activated protein C for the treatment of acute lung injury.

Authors:  Kathleen D Liu; Joseph Levitt; Hanjing Zhuo; Richard H Kallet; Sandra Brady; Jay Steingrub; Mark Tidswell; Mark D Siegel; Graciela Soto; Michael W Peterson; Mark S Chesnutt; Charles Phillips; Ann Weinacker; B Taylor Thompson; Mark D Eisner; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

8.  Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome.

Authors:  Florence Boissier; Sandrine Katsahian; Keyvan Razazi; Arnaud W Thille; Ferran Roche-Campo; Rusel Leon; Emmanuel Vivier; Laurent Brochard; Antoine Vieillard-Baron; Christian Brun-Buisson; Armand Mekontso Dessap
Journal:  Intensive Care Med       Date:  2013-05-15       Impact factor: 17.440

Review 9.  What is the clinical significance of pulmonary hypertension in acute respiratory distress syndrome? A review.

Authors:  P S Lai; C Mita; B T Thompson
Journal:  Minerva Anestesiol       Date:  2013-10-31       Impact factor: 3.051

10.  Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3.

Authors:  W Steudel; M Scherrer-Crosbie; K D Bloch; J Weimann; P L Huang; R C Jones; M H Picard; W M Zapol
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.